title: Pharmacotherapy of cholestatic liver diseases.
abstract: New insights into the molecular mechanisms of bile formation and cholestasis have provided new concepts for pharmacotherapy of cholestatic liver diseases. The major aim in all forms of cholestasis is the reduction of hepatocellular retention of bile acids and other potentially toxic constituents of bile. Reduction of hepatocellular retention may be achieved by drugs that stimulate hepatocellular secretion via the canalicular route into the bile or via the alternative route across the basolateral membrane into the blood, and by drugs that stimulate the hepatocellular metabolism of hydrophobic bile acids to hydrophilic, less toxic metabolites. In cholestatic liver diseases that start with an injury of the biliary epithelium (e.g., primary biliary cirrhosis; PBC), protection of the cholangiocytes against the toxic effects of hydrophobic bile acids is most important. When hepatocellular retention of bile acids has occurred, the inhibition of bile acid-induced apoptosis becomes another target of therapy. Ursodeoxycholic acid protects the biliary epithelium by reducing the toxicity of bile, stimulates hepatobiliary secretion by upregulating transporters and inhibits apoptosis. It is the mainstay of therapy in PBC but of benefit also in a number of other cholestatic liver diseases. New drugs such as 6-ethyl-chenodeoxycholic acid and 24-nor-ursodeoxycholic acid are being evaluated for the treatment of cholestatic liver diseases.
authors.affiliation: Department of Medicine II, Klinikum Grosshadern, University of Munich, Munich, Germany. gustav.paumgartner@med.uni-muenchen.de
authors.forename: Gustav
authors.initials: G
authors.lastname: Paumgartner
mesh_terms: D001646:Bile / Q000187:drug effects*; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D002908:Chronic Disease; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D014580:Ursodeoxycholic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*
chemical_list: D002756:Cholagogues and Choleretics; C464660:obeticholic acid; D002635:Chenodeoxycholic Acid; D014580:Ursodeoxycholic Acid; C081331:24-norursodeoxycholic acid